Nassib G. Chamoun is the Founder of HDAI, serves as its Chief Executive Officer, and is the primary inventor of its broad-based health data analytics system. Previously, Chamoun was Founder, President and CEO of Aspect Medical Systems, which he led from startup to a $100M global, publicly-traded company. Aspect’s premier product, the Bispectral Index™ (BIS™) technology, for which Chamoun was the primary inventor, is the first clinically validated direct measure of the effects of anesthetics on the brain. BIS™ technology is available in a majority of hospitals in the US, Europe and Japan, has been used clinically in approximately 50 million patients and has been the subject of more than 3,500 published articles and abstracts. BIS™ technology has been proven to reduce the risk of awareness with recall during surgery, facilitate faster wake-ups with less recovery time and reduce anesthetic use. In 2009, Chamoun guided the acquisition of Aspect Medical by Covidien, a leading $12 billion global healthcare products company. From 2009 to 2010 he assisted the CEO of Covidien in the capacity of Vice President of Technology, Research and Clinical Development.
While at Aspect Medical, Chamoun was also the inventor of RSI (or risk stratification indices), a broadly applicable and robust system for assessing hospital length of stay and mortality for groups of surgical patients based solely on administrative data. Over the years, he has published extensively on RSI in many academic-medical journals, including in collaboration with Cleveland Clinic and the Lown Institute. Chamoun presently serves as Chairman of the Board of the Lown Institute and is a member of the Northeastern University Corporation. He was a long-time Director of the Anesthesia Patient Safety Foundation.
Chamoun earned a bachelor's degree in Electrical Engineering from Northeastern University and a master's degree in Computer Engineering from Boston University. Subsequently, he was a fellow in cardiovascular physiology at the Lown Cardiovascular Laboratory at the Harvard School of Public Health and was pursuing his PhD, when he withdrew to found Aspect Medical.